Proteon logo     Print Page | Close Window

SEC Filings

10-Q
PROTEON THERAPEUTICS INC filed this Form 10-Q on 11/07/2017
Entire Document
 
 

Proteon Therapeutics, Inc.

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

(Unaudited)

 

   Three Months Ended September 30,  Nine Months Ended September 30,
   2017  2016  2017  2016
Operating expenses:                    
Research and development  $10,336   $4,842   $18,473   $14,432 
General and administrative   1,970    2,324    6,299    7,407 
Total operating expenses   12,306    7,166    24,772    21,839 
Loss from operations   (12,306)   (7,166)   (24,772)   (21,839)
Other income (expense):                    
Investment income   83    46    161    155 
Other (expense) income, net   (84)   13    198    120 
Total other (expense) income   (1)   59    359    275 
Net loss  $(12,307)  $(7,107)  $(24,413)  $(21,564)
Unrealized (loss) gain on available-for-sale investments   -    (2)   (7)   19 
Comprehensive loss  $(12,307)  $(7,109)  $(24,420)  $(21,545)
Reconciliation of net loss to net loss attributable to common stockholders                    
Net loss  $(12,307)  $(7,107)  $(24,413)  $(21,564)
Accretion of convertible preferred stock   (6,747)   -    (6,747)   - 
Net loss attributable to common stockholders  $(19,054)  $(7,107)  $(31,160)  $(21,564)
Net loss per share attributable to common stockholders - basic and diluted  $(1.08)  $(0.43)  $(1.82)  $(1.30)
Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted   17,574,371    16,582,276    17,158,032    16,550,483 
                     
Supplemental disclosure of stock-based compensation expense and loss from currency forward contracts:                    
Included in operating expenses, above, are the following amounts for non-cash stock based compensation expense:                    
Research and development  $235   $168   $841   $797 
General and administrative   512    519    1,618    1,702 
Total  $747   $687   $2,459   $2,499 
                     
Included in other (expense) income, net, above, are the following amounts from forward foreign currency contracts:                    
Realized losses from forward foreign currency contracts  $-   $(4)  $-   $(8)
Unrealized (losses) gains from forward foreign currency contracts   -    2    -    127 
Total  $-   $(2)  $-   $119 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6